

Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?

Peter Ferenci*

Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria

Abstract

Within 2 years after licensing peginterferon/ribavirin and first generation protease inhibitors (telaprevir, boceprevir) for treatment of chronic hepatitis C the speed of development of new treatments has substantially increased.

Citation:

8. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. *N Engl J Med* 368: 34-44.
9. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. *Hepatology* 2013;58 (Suppl):733A
10. Younossi ZM, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, et al. (2013) Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). *J Hepatol* .
11. Curry MP, Forns X, Chung RT, Terrault N, Brown RS, et al. (2013) Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation. *Hepatology*58:314A
12. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. *N Engl J Med* 370: 211-221.
13. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. *N Engl J Med* 366: 216-224.
14. Chayama K, Suzuki Y, Ikeda K, Toyota J, Karino Y, et al.(2013) All-oral Combination of DaclatasvirPlusAsunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial. *Hepatology*58: 313A
15. Lawitz E, Vierling JM, Murillo A, Kugelmas M, Gerstoft J et al.(2013) High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study. *Hepatology* 58:244
16. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, et al. (2013) Phase 2b study of the interferon-free and ribavirin-free combination of 7